Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 1130 - 4871 Shell Road RICHMOND BC V6X 3Z6 |
Tel: | N/A |
Website: | https://eleotin.ca |
IR: | See website |
Key People | ||
Yunji Kim President, Chief Financial Officer, Corporate Secretary, Director | Youngsoo Kim Chief Executive Officer, Director |
Business Overview |
Eastwood Bio-Medical Canada Inc. is engaged in marketing and distributing natural health products in North America. It is a licensed distributor of the Eleotin line of products, which include formulations based on natural ingredients that are presented in tea or capsule forms. The Eleotin products include natural remedies for certain metabolic disorders such as blood glucose disorders, hypertension and obesity, and can be used as a dietary supplement. Its licensed products include Eleotin A 700, which is a treatment for spleen deficiency, lack of appetite and fatigue; Eleotin AL88, a laxative; Eleotin Cal20, for bone and teeth maintenance; Eleotin V3D, for the development and maintenance of bones, teeth and good health; Eleotin G2000, for cardiovascular health; Eleotin H55, for sedative and tension relief, and Eleotin Zn330, for the tissue formation and metabolism. In addition, it offers Eleotin Bentley to promote healthy glucose levels and Eleotin LBM for hypertension relief. |
Financial Overview |
For the fiscal year ended 31 October 2023, Eastwood Bio-Medical Canada Inc revenues decreased 33% to C$868K. Net loss increased from C$150K to C$547K. Revenues reflect Asia segment decrease of 34% to C$616K, Canada segment decrease of 45% to C$113K. Higher net loss reflects Wages and Salaries increase of 11% to C$504K (expense), Office increase from C$9K to C$55K (expense). Basic Earnings per Share excluding Extraordinary Items totaled to -C$0.01. |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $55.15M as of Oct 31, 2023 |
Annual revenue (TTM): | $0.87M as of Oct 31, 2023 |
EBITDA (TTM): | -$0.43M as of Oct 31, 2023 |
Net annual income (TTM): | -$0.55M as of Oct 31, 2023 |
Free cash flow (TTM): | -$0.02M as of Oct 31, 2023 |
Net Debt Last Fiscal Year: | $0.04M as of Oct 31, 2023 |
Shares outstanding: | 68,885,969 as of Oct 31, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |